Fortitude Family Office’s Amylyx Pharmaceuticals AMLX Stock Holding History

Fortitude Family Office’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.53K	Buy	+87	New	+$2.31K	﹤0.01%	1904

Other funds holding AMLX

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

PPWP

Premier Path Wealth Partners Madison, New Jersey $856M AUM 23.55% 1-Year Est. Return

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

VSQM

V-Square Quantitative Management Chicago, Illinois $1.09B AUM 23.97% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CAIM

Catherine Avery Investment Management Longboat Key, Florida $116M AUM 31.75% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Fortitude Family Office's AMLX Position: Q3 2026 in Review

Fortitude Family Office opened a new position in Amylyx Pharmaceuticals (AMLX) in Q3 2026: 87 shares worth $2.53K. The stake represents ﹤0.01% of the portfolio and ranks #1904 among its holdings.

12 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

Fortitude Family Office held 87 shares of Amylyx Pharmaceuticals worth $2.53K as of Q3 2026.
Amylyx Pharmaceuticals was a new Fortitude Family Office position in Q3 2026.
Amylyx Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #1904 holding.
12 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.